Evaluation of the Effectiveness of Meloxicam in the Treatment of Patients with Rheumatoid Arthritis in Older Age Groups

Abstract

The article presents the results of a study of the clinical efficacy and tolerability of a new generation of non-steroidal anti-inflammatory drugs (NSAIDs) meloxicam 10 mg cyclooxygenase inhibitors (COX-2 inhibitor) in the treatment of rheumatoid arthritis in patients of older age groups. In 35 patients with rheumatoid arthritis (RA) of both sexes aged 45-65 years, an open clinical study of the action of meloxicam was performed. During the treatment period, basic therapy, drugs that improve heart function, diuretics and antiplatelet agents were prescribed. Controlled clinical and laboratory parameters were assessed before the inclusion of patients in the study and after the end of therapy.